Search Results

You are looking at 1 - 10 of 36 items for :

  • Medical and Health Sciences x
Clear All

Macer, G. Sz.: Cradles, or Ode on The Birth of the Lord. [Cunae seu in Nativitatem Dominicam Ode.] Lazarus Andreae, Cracoviae, 1556. [Latin] 3 Wisłocki, W.: Book of

Restricted access
Orvosi Hetilap
Authors: Jana Balegová, František Šimon and László András Magyar

References 1 Bocatius, J.: The complete poetical works. [Opera quae exstant omnia poetica.] 1, 2. Ed. Csonka, F. Akadémiai Kiadó, Budapest, 1990. [Latin

Open access

, chapter 9. Collection of Hungary’s Historic Public Health Legislation. [Decretales pontifici Gregorii IX. liber 3, titulus 50, caput 9.] Codex sanitario-medicinalis Hungariae. Budae, 1852–1861; I–VII/I: 42. [Latin

Open access

Commercial anti-uric acid diets for dogs may contain insufficient protein to sustain growth and lactation. In order to investigate the efficacy of an experimental purine-free diet moderately low in protein, its effect on urinary uric acid excretion was compared with that of a commercial dog food and a commercial low-protein anti-uric acid diet. The experimental diet, commercial dog food and commercial anti-uric acid diet contained 10.0, 12.8 and 5.0 g crude protein/MJ metabolizable energy, respectively. Twelve Dalmatian dogs were subjected to a 3 × 3 Latin square study. Although the plasma uric acid concentration was significantly lower when the dogs were fed either the commercial anti-uric acid diet (18.7 ± 6.0 µmol/l, mean ± SD, n = 12) or the experimental diet (19.2 ± 8.3 µmol/l), when compared to the commercial dog food (29.2 ± 11.1 µmol/l), no significant decrease of uric acid concentration in urine collected before the morning meal was seen. The average concentration of urinary uric acid was 60 µmol/l. There was a significant increase in the urea:creatinine ratio in urine when the dogs were fed the experimental diet compared to the commercial anti-uric acid diet, confirming that the experimental diet contained more protein. The experimental diet lowered plasma uric acid and was relatively high in protein and thus may be suitable for use in growing and lactating dogs to prevent ammonium urate urolithiasis.

Restricted access

. [Hungarian] 3 Szabó M. Latin medical and public language terms adopted in Hungarian (Part 2). [A magyar nyelvben meghonosodott latin orvosi és köznyelvi kifejezések (2. rész).] Magyar

Restricted access

The role of oxytocin (OT) in the regulation of prostaglandin F (PGF ) secretion during luteolysis in gilts was studied using a highly specific OT antagonist (CAP-581). In Experiment 1 gilts on Days 14 to 19 of the oestrous cycle in Latin square design were used, to determine the dose and time of application of OT and CAP. In Group I (n = 6) gilts were treated intravenously with saline or with 10, 20 and 30 IU of OT. Concentrations of the main PGF metabolite i.e. 13,14-dihydro-15-keto-prosta-glandin F (PGFM) were measured in blood samples as uterine response to the treatment. Twenty IU of OT was the most effective to stimulate PGFM release and this dose was used after CAP treatment in gilts of Groups II, III and IV. Gilts of Group II (n = 3) were injected into the uterine horns (UH) with saline (5 ml/horn) or CAP (2 mg, 3 mg and 4 mg; half dose/horn) and OT was injected (i.v.) 30 min thereafter. Any of the CAP doses given into the UH affected PGFM plasma concentrations stimulated by OT. In Group III (n = 4) gilts were infused (i.v.) for 30 min with CAP (9 mg, 14 mg and 18 mg/gilt) followed by 20 IU of OT. All doses of CAP effectively inhibited OT-stimulated PGF release, therefore 9 mg was selected for the further studies. Gilts of Group IV (n = 4) received OT 4, 6 and 8 h after CAP to define how long CAP blocks the OT receptors. Concentrations of PGFM increased after any of this period of time. Thus, we concluded that 9 mg of CAP infused every 4 h will effectively block OT receptors. In Experiment 2, gilts (n = 4) received CAP as a 30-min infusion every 4 h on Days 12-20 of the oestrous cycle. Control gilts (n = 3) were infused with saline. CAP infusions diminished the height of PGFM peaks (P < 0.05). Frequency of the PGFM (P < 0.057) and OT (P < 0.082) peaks only tended to be lower in the CAP-treated gilts. Peripheral plasma concentrations of progesterone (P4) and oestradiol-17β (E2) and the time of luteolysis initiation as measured by the decrease of P4 concentration were the same in CAP-and saline-treated gilts. The macroscopic studies of the ovaries in gilts revealed lack of differences between groups. We conclude that OT is involved in the secretion of luteolytic PGF peaks but its role is limited to controlling their height and frequency. Blocking of OT receptors did not prevent luteolysis in sows.

Restricted access
Orvosi Hetilap
Authors: Annamária Bakos, Árpád Szomor, Tamás Schneider, Zsófia Miltényi, Imelda Marton, Zita Borbényi, Judit Pammer, László Krenács, Enikő Bagdi and Klára Piukovics

Absztrakt:

Bevezetés: Az extranodalis nasalis típusú natural killer/T (NK/T) sejtes lymphoma (ENKTL) a T-sejtes lymphomák egyik ritka agresszív megjelenésű formája, amely elsősorban sinonasalis és nasopharynx kiindulású. Bár előfordulása ritka a fejlett nyugati országokban, kezelése a hagyományos, agresszív lymphomákban alkalmazott antraciklintartalmú kemoterápiával csekély hatékonyságú. Célkitűzés: ENKTL-esetek előfordulása hazai hematológiai centrumok által gondozott non-Hodgkin-lymphomás betegek között. Módszer: A szerzők négy magyarországi hematológiai centrumban 2003–2015 között kezelt 20 ENKTL-beteg klinikai adatait elemezték. A betegek között 12 férfi és 8 nő volt, medián életkor 49,5 év (22–84 év). Eredmények: Tíz esetben a betegség lokalizált (I–II. stádiumban) volt a diagnózis idején. Kemoterápiás kezelésben részesült 17 beteg (11 CHOP, CHOP-szerű, kettő hyper-CVAD, egy ProMACECytaBom, egy SMILE, kettő egyéb), amelyet hat esetben érintett mezős besugárzással (IFRT) egészítettek ki (40–46 Gy). Az első vonalbeli kezelésre kilenc beteg komplett (CR), három parciális remisszióba (PR) került, három progrediált, két esetben stabil volt a betegség. A medián követési idő 32 (3–113) hónap volt. Öt beteg progresszió, recidíva miatt második vonalban újabb kezelésben részesült (kettő DHAP, egy VIM, egy hyper-CVAD, egy ProMACECytaBom). Második vonalbeli kezelésre CR nem jött létre egy betegben sem. Két esetben első CR-ben autológ őssejt-transzplantáció történt. Következtetés: Az ENKTL kezelésében hatékonyabbak a nem antraciklintartalmú kemoterápiás kezelések. Elsősorban L-aszparagináz-alapú kombinált kemoterápia és egyidejű vagy szekvenciális kemo-radioterápia alkalmazásával a túlélés és CR aránya javítható. Orv Hetil. 2017; 158(41): 1635–1641.

Restricted access
Acta Veterinaria Hungarica
Authors: István Kiss, Tamás Mató, Zalán G. Homonnay, Judit Kojer, Attila Farsang, Ádám Bálint and Vilmos Palya

. K. A. and van der Heijden , H. M. J. F. ( 2010 ): Infectious bronchitis virus in Asia, Africa, Australia and Latin America – History, current situation and control measures . Braz. J. Poultry Sci. 12 , 97 – 106

Restricted access

Health Legislation. [Codex sanitario-medicinalis Hungariae.] Budae, 1852–1861. II. 456. [Latin] 9 Győry H. Origin of medicines, the Ebers-papyrus – an old Egyptian

Open access

. , Torgerson , T. R. , Carvalho , B. T. , Espinosa-Rosales , F. , Ochs , H. D. , Condino-Neto , A. : First report of the hyper-IgM syndrome registry of the Latin American Society for Immunodeficiencies: Novel mutations, unique infections, and outcomes

Restricted access